Saccharomyces cerevisiae: An efficient tool and model system for anticancer research;La levure Saccharomyces cerevisiae : Un modèle et un outil performant pour la recherche en oncologie

Bulletin du Cancer

Volumn 91, Issue 2, 2004, Pages 133-139

  Kurtz, Jean Emmanuel ^a,b   Dufour, Patrick ^a   Duclos, Brigitte ^a   Bergerat, Jean Pierre ^a   Exinger, Françoise ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Cancerogenese Mutagenese Molec S   (France)

Author keywords

Anticancer drugs; Cancer; Genetics; Metabolism; Saccharomyces cerevisiae

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; CAPECITABINE; CYTOCHROME P450 2A6; DNA; GEMCITABINE; PYRIMIDINE; UFT;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CELL CYCLE PHASE; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; DNA DETERMINATION; DNA REPAIR; DRUG SCREENING; FUNGUS MUTANT; GENE THERAPY; HUMAN; METABOLIC REGULATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SACCHAROMYCES CEREVISIAE; SYSTEMATIC REVIEW; YEAST;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; PHENOTYPE; PRODRUGS; PYRIMIDINES; SACCHAROMYCES CEREVISIAE;

EID: 1842453222     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Kurtz JE, Exinger F, Erbs P, Jund R. New insights into the pyrimidine salvage pathway of Saccharomyces cerevisiae : requirement of six genes for cytidine metabolism. Curr Genet 1999 ; 36 : 130-6.
2. Kurtz JE, Exinger F, Erbs P, Jund R. The URH1 uridine ribohydrolase of Saccharomyces cerevisiae. Curr Genet 2002 ; 41 : 132-41.
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998 ; 34 : 1274-81.
4. Plunkett W, Huang P, Xu XZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine : metabolism, mechanisms of action and self-potentiation. Sem Oncol 1995 ; 22 : 10-3.
5. Kurtz JE, Adenis A, Bugat R, Négrier S, Trillet-Lenoit V, Kayitalire L, et al. Compassionate use of gemcitabine in advanced pancreatic cancer : a French multicentric study. Bull Cancer 1999 ; 86 : 202-6.
6. Kurtz JE, Andres E, Natarajan-Amé S, Noël E, Dufour P. Oral chemotherapy in colorectal cancer treatment : review of the literature. Eur J Int Med 2003 ; 14 : 18-25.
7. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients : implications for treatment with fluorouracil. J Clin Oncol 1994 ; 12 : 2035-42.
8. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994 ; 12 : 2640-7.
9. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach : a predictor for primary tumor response and overall survival. J Clin Oncol 1996 ; 14 : 176-82.
10. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsa-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 ; 6 : 1322-7.
11. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003 ; 88 : 648-53.
12. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002 ; 20 : 3617-27.
13. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic cancer. J Clin Oncol 2002 ; 20 : 3605-16.
14. Wera S, Degreve B, Balzarini J, De Clercq E, Thevelein JM, Neyts J. Budding yeast as a screening tool for discovery of nucleoside analogs for use in HSV-1 TK suicide-gene therapy. Biotechniques 1999 ; 27 : 772-7.
15. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, et al. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 2002 ; 9 : 844-9.
16. Block A, Freund CT, Chen SH, Nguyen KP, Finegold N, Windler E. Gene therapy of metastatic colon carcinoma : regression of multiple hepatic metastases by adenoviral expression of the bacterial cytosine deaminase. Cancer Gene Ther 2000 ; 7 : 438-45.
17. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Human Gene Ther 1999 ; 10 : 1993-2003.
18. Erbs P, Exinger F, Jund R. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr Genet 1997 ; 31 : 1-6.
19. Kievit E, Nyati MK, Ng N, Stegman LD, Parsels J, Ross BD, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000 ; 60 : 6649-55.
20. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000 ; 60 : 3813-22.
21. Kokoris MS, Black ME. Characterization of herpes simples virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 2002 ; 11 : 2267-72.
22. Kurtz JE, Black M. Enhancement of suicide gene prodrug activation by random mutagenesis. In : Suicide gene therapy : methods and protocols for cancer. Methods in Molecular Medecine Series, Humana press Inc., Totowa New Jersey, USA, 2003 (In press).
23. Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000 ; 60 : 328-33.
24. Launhardt H, Hinnen A, Munder T. Drug-induced phenotypes provide a tool for the functional analysis of yeast genes. Yeast 1998 ; 14 : 935-42.
25. Van Hille B, Van Hille BT. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II : a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol 1998 ; 42 : 345-56.
26. Hartwell LH, Szankaski P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997 ; 278 : 1064-8.
27. Perego P, Jimenez GS, Gatti L, Howell SB, Zunino F. Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev 2000 ; 52 : 477-91.
28. Debusshe L. Methods for the preclinical screening of new anticancer agents. Bull Cancer 2001 ; 88 : 67-74.
29. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med 1998 ; 4 : 1235-6.
30. Hugues TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armow CD, et al. Functional discovery via a compendum of expression profiles. Cell 2000 ; 102 : 109-26.
31. Kolaczkowski M, Goffeau A. Active efflux by multidrug transporters as one of the strategies to evade chemotherapy and novel practical implications of yeast pleiotropic drug resistance. Pharmacol Ther 1997 ; 76 : 219-42.
32. Norman TC, Smith DL, Sorger PK, Drees BL, O'Rourke S, Hugues TR, et al. Genetic selection of peptide inhibitors of biological pathways. Science 1999 ; 285 : 591-5.
33. Larkin K, Schweizer M. Development of a yeast-based assay system for monitoring microsatellite instability. FEMS Microbiol Let 1999 ; 176 : 205-12.
34. Ceraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, et al. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol 2003 ; 148 : 99-109.